Spotlight on Epicutaneous Immunotherapy

DBV Technologies, a biopharmaceutical firm specializing in innovative food allergy treatments, is set to present at the Citizens JMP Life sciences Conference. The company’s Managing Director, Daniel Tassé, will participate in a “Fireside Chat” on May 7th in New York City, offering insights into their pioneering work.

The session will be streamed live on the DBV Technologies website,providing broad access to investors adn interested parties. A replay will be available for 90 days following the event, ensuring continued access to the presentation.

Viaskin® Patch: A Novel approach to Food Allergy Desensitization

DBV Technologies is particularly focused on addressing food allergies through its proprietary Viaskin® technology. This innovative approach utilizes epicutaneous immunotherapy (EPIT), delivering allergenic proteins directly to the skin to desensitize patients.

The Viaskin® patch,the cornerstone of this technology,aims to gradually reduce sensitivity to specific allergens,potentially offering a safer and more convenient alternative to traditional oral immunotherapy. This method seeks to train the immune system to tolerate allergens without triggering severe allergic reactions.

The Viaskin® patch aims to desensitize patients to allergens.

The Growing Need for Food Allergy Solutions

The prevalence of food allergies is a growing global concern. According to recent studies, approximately 32 million Americans have food allergies, including 1 in 13 children. This translates to roughly two students in every classroom. The economic burden of food allergies is also notable, costing the US healthcare system billions of dollars annually.

DBV Technologies’ research and growth efforts are particularly relevant in this context, as they strive to provide effective and accessible treatments for individuals living with food allergies.Their participation in the Citizens JMP Life Sciences Conference underscores their commitment to sharing their progress and engaging with the broader scientific and investment communities.

DBV Technologies: A Clinical-Stage Biopharmaceutical Leader

Listed on both Euronext and NASDAQ, DBV Technologies is a clinical-stage biopharmaceutical company dedicated to transforming the lives of individuals with food allergies. Their focus on innovative technologies like Viaskin® positions them as a key player in the evolving landscape of allergy treatment.

The company’s presentation at the Citizens JMP Life Sciences Conference provides a valuable possibility to learn more about their ongoing research, clinical trials, and future plans for addressing the unmet needs of the food allergy community. Investors and those interested in the future of food allergy treatment are encouraged to tune in to the live webcast or access the replay.